Molecular profiling of glioblastomas has revealed the presence of key signaling hubs that contribute to tumor progression and acquisition of resistance. One of these main signaling mechanisms is the nuclear factor-kappa B (NF-κB) pathway, which integrates multiple extracellular signals into transcriptional programs for tumor growth, invasion and maintenance of the tumor-initiating population. We show here that an extracellular protein released by glioblastoma cells, fibulin-3, drives oncogenic NF-κB in the tumor and increases NF-κB activation in peritumoral astrocytes. Fibulin-3 expression correlates with a NF-κB-regulated 'invasive signature' linked to poorer survival, being a possible tissue marker for regions of active tumor progression. Accordingly, fibulin-3 promotes glioblastoma invasion in a manner that requires NF-κB activation both in the tumor cells and their microenvironment. Mechanistically, we found that fibulin-3 activates the metalloprotease ADAM17 by competing with its endogenous inhibitor, TIMP3. This results in sustained release of soluble tumor necrosis factor alpha (TNFα) by ADAM17, which in turn activates TNF receptors and canonical NF-κB signaling. Taken together, our results underscore fibulin-3 as a novel extracellular signal with strong activating effect on NF-κB in malignant gliomas. Because fibulin-3 is produced de novo in these tumors and is absent from the normal brain, we propose that targeting the fibulin-3/NF-κB axis may provide a novel avenue to disrupt oncogenic NF-κB signaling in combination therapies for malignant brain tumors.
INTRODUCTION
Glioblastomas (GBMs) are the most common primary tumors in the central nervous system (CNS), originating from transformed, glial-committed, progenitor cells. 1 Their invasive behavior and resistance to chemotherapy make them one of the solid tumors with worst prognosis, 2,3 resulting in a median survival time of approximately 15 months. 4 GBMs can be classified into subtypes with well-defined transcriptional signatures and differences in invasive behavior, angiogenesis and apoptotic resistance, all of which may help tailor-targeted therapies more accurately. [5] [6] [7] GBMs are driven by a relatively small number of major signaling hubs that regulate their phenotype and contribute to resistance and development of malignant features. 5, 8 One of these hubs is the nuclear factor-kappa B (NF-κB) pathway, which responds to multiple extracellular signals by activating transcriptional programs that mediate inflammatory and immune responses. 9 This pathway has a key role in GBM growth and invasion via enhancement of cell proliferation and apoptotic resistance, release of pro-inflammatory cytokines, and upregulation of metalloproteases in the tumor microenvironment. 10, 11 Recent work has also demonstrated that NF-κB regulates the conversion of the proneural subtype of GBMs into the more aggressive mesenchymal subtype, as well as the radio-resistance of these aggressive GBMs. 12 Expression of NF-κB-dependent genes is driven by the active forms of NF-κB transcription factors (RelA/p65 and NF-κB1/p105), which are upregulated in GBM specimens and glioma cells compared with normal astrocytes. 13, 14 NF-κB upregulation typically follows the activation of tumor necrosis factor (TNF) and interleukin-1 (IL-1) receptors in response to cytokines, but this pathway can also be activated by cell-intrinsic mechanisms in GBM cells, mediated by EGFR (epidermal growth factor receptor)/ Akt signaling that can bypass inhibition of TNF receptors. 11, 15 However, there is little knowledge about the regulatory mechanisms that keep sustained NF-κB activity in mesenchymal GBMs and their microenvironment.
A majority of GBMs secrete the glycoprotein fibulin-3, which is a component of the fibrillar extracellular matrix (ECM) in connective tissues but is absent from normal brain. 16 Fibulin-3 expressed in high-grade gliomas gains a novel function as autocrine/paracrine enhancer of Notch signaling in tumor cells and adjacent endothelial cells, leading to increased tumor growth, invasion and angiogenesis. 17, 18 We and others have shown that fibulin-3 also promotes resistance to temozolomide treatment and is particularly upregulated in mesenchymal GBMs. 17, 19 Because fibulin-3 appears strongly associated with the malignant progression of gliomas, we investigated whether this protein could regulate NF-κB signaling and the downstream pro-tumoral effects of this pathway in GBM.
We report here that fibulin-3 has a novel and remarkable driving effect on canonical NF-κB signaling, acting not only in the tumor but also in peritumoral glia. Fibulin-3 expression correlates with an increased pro-invasive NF-κB signature in experimental models and clinical data sets; accordingly, this ECM protein promotes GBM invasion by ADAM17-dependent activation of NF-κB. These results suggest that fibulin-3 is a novel oncogenic factor regulating the major canonical NF-κB axis in GBM.
RESULTS

Fibulin-3 regulates NF-κB signaling in GBM cells
Overexpression of fibulin-3 cDNA in a conventional GBM cell line (U251 cells 16 ) caused remarkable activation of canonical NF-κB signaling, as observed by increased phosphorylation of the TNFR adaptor protein RIP2, IKK kinases, and the transcription factor p65/ RelA, as well as degradation of the NF-κB inhibitor IκBα (Figures 1a  and c ). In addition, overexpression of fibulin-3 not only increased the levels of phospho-p65 but also the translocation of this transcription factor to the nucleus, mimicking the stimulation of NF-κB by TNFα (Figures 1d and e ). In contrast, when fibulin-3 expression was transiently downregulated in the same cells, the phosphorylation of RIP2, IKK and p65 was markedly decreased, indicating inhibition of NF-κB signaling (Figures 1b and c) . Strikingly, fibulin-3 knockdown also rendered this pathway insensitive to exogenous TNFα, reducing or preventing activation of RIP2, IKK and p65 even when TNFα was added to the cultures. The dominant-negative effect of fibulin-3 knockdown on TNFαactivated NF-κB signaling was also observed in mesenchymal GBM stem cells ( Supplementary Figures 2A-C) . We further confirmed that fibulin-3 specifically activated canonical (that is, IκBαdependent) NF-κB signaling because its effect was prevented by transfection of a dominant-negative 'super-repressor' form of IκBα that prevents p65 phosphorylation (Supplementary Figure 2D) . Moreover, fibulin-3 transfection did not increase the phosphorylation of RelB, a mediator of non-canonical NF-κB signaling (Supplementary Figure 2E) .
Activation of NF-κB signaling by fibulin-3 resulted in increased NF-κB transcriptional activity, measured with a NF-κB luciferase reporter in U251 cells (Supplementary Figure 2F ) and in a second GBM cell line, CNS1 (Figure 1f ). These results were observed after fibulin-3 overexpression as well as by adding soluble, purified fibulin-3 in the CNS1 cultures ( Figure 1f ). We also replaced the luciferase reporter gene with secreted alkaline phosphatase (SEAP), which allowed us to collect conditioned medium from transfected cells and monitor NF-κB transcriptional activity over time. Stimulation with fibulin-3 or TNFα increased SEAP release with similar fast kinetics and did not show additive effects, suggesting that they shared a common mechanism (Supplementary Figure 3A ). More importantly, fibulin-3 knockdown reduced NF-κB-dependent SEAP release and significantly diminished the effects of TNFα (Supplementary Figure 3B ), in agreement with our dominant-negative effect observed in Figure 1b .
We next verified whether fibulin-3 had specific impact on transcriptional targets of NF-κB associated with cell motility and adhesion because those processes are enhanced by fibulin-3 in GBM. 16 U251 cells overexpressing fibulin-3 or stimulated with soluble fibulin-3 showed increased expression of the pro-invasive genes tenascin-C (TNC), myosin light-chain kinase (MLCK) and the matrix metalloproteases MMP9 and MMP13, all of which were also upregulated by TNFα ( Figure 1g ). Conversely, fibulin-3 knockdown caused significant downregulation of those genes. Together, these collective results demonstrated that fibulin-3 is a dominant regulator of NF-κB activity in GBM cells.
Fibulin-3 correlates with NF-κB upregulation in GBM and its microenvironment To validate our results in vivo, we implanted invasive, fibulin-3overexpressing, CNS1 cells intracranially in athymic mice. We have previously demonstrated that fibulin-3 overexpression leads to larger, more invasive, and more vascularized CNS1 tumors. 16, 18 Here, we focused on expression of p65 as marker of NF-κB activation in the tumor core and surrounding peritumoral tissue.
Analysis of tissue sections from similar-sized tumors revealed a significant increase of p65 in the core of fibulin-3-overexpressing tumors (Figures 2a,b ,g). Total expression of p65 was also increased in the border of these tumors but did not reach statistical significance ( Figure 2g ). However, when we focused specifically on GFAP-positive astrocytes in the tumor border ( Figures 2c-f ), we confirmed that those cells had significant increase of p65 in fibulin-3-overexpressing tumors (Figure 2h ). Analysis of higher magnification images revealed that the increased p65 significantly co-localized with nuclei both in the core and border of fibulin-3overexpressing tumors, indicating increased activation and nuclear localization of this NF-κB transcription factor both in GBM and astroglial cells ( Figure 2i ).
To confirm that fibulin-3 could activate NF-κB signaling in tumor-associated neural cells, we added purified fibulin-3 to primary cultures of brain astrocytes and brain microvascular endothelial cells, none of which express endogenous fibulin-3. As expected, fibulin-3 increased phospho-p65 in both cell types ( Figure 2j ). Moreover, fibulin-3 also increased the expression of NF-κB-dependent pro-invasive genes in astrocyte cultures ( Figure 2k ) matching our previous result with GBM cells.
Fibulin-3 correlates with a pro-invasive NF-κB signature in GBM Next, we studied the association of fibulin-3 (gene EFEMP1) with NF-κB transcription factors and NF-κB-dependent genes using transcriptomics data from the REMBRANDT and TCGA repositories. Fibulin-3 and its close homolog fibulin-4 (EFEMP2) showed significant positive correlation with canonical NF-κB transcription factors and the pro-invasive genes that we had assayed in Figure 1g , except MMP13, which was expressed at very low levels in GBMs (Supplementary Figure 4A and B). Cluster analysis of those genes using TCGA microarray data revealed two welldefined patient populations with high and low gene co-expression ( Figure 3a ) and significantly different survival curves ( Figure 3b ).
Further analysis of fibulin-3 and NF-κB p65 (gene RELA) expression showed that the average co-expression of both genes was highest in the mesenchymal subtype of GBMs (Figure 3c ), which were the predominant subtype in the patient population with poorer survival. Moreover, analysis of intratumoral expression from an independent data set (IVY Glioblastoma Atlas Project) confirmed the significant correlation of both genes ( Figure 3d ) and their preferential co-expression in perinecrotic pseudopalisade areas, which typically contain a 'escaping' population of migratory glioma cells. 20 Because the NF-κB pathway regulates the expression of hundreds of genes, we next asked whether fibulin-3 expression had preferential correlation with specific transcriptional programs or acted as an indiscriminate NF-κB activator. To answer this, we used publically available surveys to compile a list of 348 genes directly regulated by NF-κB (Supplementary Table 3 ) and correlated their expression against fibulin-3 using TCGA microarray data (Supplementary Table 3 ). We then chose two groups of 100 genes with the highest and lowest correlation against fibulin-3 and used Ingenuity Pathway Analysis to identify relevant pathways and cellular functions represented in each group (Supplementary Table 4 ). The analysis suggested that the top NF-κB-dependent cellular functions highly correlated with fibulin-3 are those involved in cell motility or invasion, matching the known function of fibulin-3 in GBM. On the other hand, NF-κB-regulated functions poorly correlated with fibulin-3 included cell proliferation and signaling in the nervous and immune systems ( Figure 3e ). We further confirmed that genes identified as poorly correlated with fibulin-3 (for example, cytokines IL-2, IL-12B and IL-17) effectively did not change expression after fibulin-3 overexpression or knockdown in U251 cells (Supplementary Figure 4C ). for each phospho-protein band was normalized to its own total protein (or actin for IκB); bars represent fold-change (in log scale) in OD for each condition compared against their control (control transfections were given arbitrary OD value of 1). (d) Treatment of U251 cells with fibulin-3 (2 h) or TNFα (30 min) increased the translocation of p65 to the nucleus. (e) Quantification of nuclear p65 in cells from d, co-localized with nuclear DAPI stain (***P o0.001, one-way analysis of variance (ANOVA)). (f) CNS1 cells carrying a NF-κB-dependent reporter were cultured with no treatments (vehicle), transfected with control or fibulin-3 cDNAs (control cells and fib-3 OE cells), or treated with purified fibulin-3 (300 ng/ml × 4 h). Stimulation with transfected or exogenous fibulin-3 resulted in reporter activation (**Po 0.01; ***P o0.001, one-way ANOVA). Similar results were observed in U251 cells (Supplementary Figure 2F ). (g) U251 cells were treated with TNFα, soluble purified fibulin-3 (sol. fib-3), or transfected with fibulin-3 cDNA or siRNA (or their controls), and processed for qRT-PCR. Fibulin-3 levels regulated the expression of the NF-κB-dependent genes TNC, MLCK, MMP9 and MMP13. Results were compared by one-way ANOVA for each gene (*Po 0.05; **P o0.01; # Po0.001).
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The pro-invasive effects of fibulin-3 require NF-κB signaling Fibulin-3 predominantly regulates cell adhesion and invasion in GBM 16 and maintains the viability of the GBM stem cell population, even though it does not increase GBM cell proliferation. 17 Therefore, we next investigated if these phenotypic effects were mediated NF-κB as predicted from our in silico data.
We first measured the effect of fibulin-3 on cell adhesion and observed that fibulin-3-overexpressing U251 cells had increased Fibulin-3 regulates NF-κB signaling in glioma adhesion to fibronectin-coated substrates, as expected ( Figure 4a ). However, this effect was completely abolished when the cells were co-transfected with p65 siRNA or with the NF-κB 'superrepressor' form of IκB. Next, we measured cell invasion using highly invasive CNS1 cells seeded on cultured brain slices, which provide an accurate ex vivo model for GBM dispersion in neural tissue 21 (U251 cells are poorly invasive in vivo and do not disperse in cultured brain tissue). Fibulin-3-overexpressing CNS1 cells dispersed much further than control cells (Figure 4b ), but this effect was abolished by co-transfection of p65 siRNA (Figure 4c ) or by treating the cultures with the NF-κB inhibitor CAPE 22 (Figure 4d ). A more specific NF-kB inhibitor, BAY-11-7082, was also assayed but caused unavoidable toxicity in the cells and cultured brain tissue (Supplementary Figure 5A ). Together, results from Figures 4a-d confirmed that fibulin-3 drives a NF-κBdependent, pro-invasive mechanism in GBM cells. In contrast, although fibulin-3 knockdown reduced GBM stem cell viability as previously described, 17 this effect was independently rescued by TNFα ( Supplementary Figure 5B ), suggesting that fibulin-3 effects on GBM viability were probably not dependent on, or correlated with, NF-κB signaling, as predicted from Figure 3e .
Finally, we evaluated whether the pro-invasive effect of fibulin-3 was tumor cell-intrinsic or could also involve NF-κB regulation in peritumoral brain tissue as suggested from our results in vivo ( Figure 2 ). We repeated our brain slice invasion assays using neonatal brain tissue from NF-κB-deficient mice lacking both TNFR1 and p65 expression. 23 Remarkably, CNS1 cells were unable to invade through NF-κB-deficient brain slices and the proinvasive effect of fibulin-3 was completely suppressed (Figure 4f ). Taken together, our results suggest that the leading function of fibulin-3 as pro-invasive factor in GBMs is mediated by its ability to drive NF-κB-dependent 'pro-invasion programs' both in tumor cells and their microenvironment.
NF-κB regulation by fibulin-3 involves control of CYLD expression and TACE activity
We finally investigated the mechanism of NF-κB activation by fibulin-3, focusing on possible mechanisms triggered by this ECM protein at the cell membrane level.
Fibulin-3 can compete with Notch inhibitors to directly activate Notch signaling in GBM, increasing the expression of Notchregulated genes such as the transcription factors Hes-1. 17, 18 Work in T-cell leukemia has shown that Hes-1 represses the expression of the de-ubiquitinase CYLD, 24 which is a NF-κB inhibitor that acts by preventing degradation of IκB. 25 Therefore, we reasoned that fibulin-3 stimulation of Notch could downregulate CYLD and indirectly activate NF-κB.
To test this hypothesis, we first confirmed that CYLD knockdown was sufficient to increase phosphorylation of p65 in U251 cells (Figure 5a ). Then, as predicted, we observed that fibulin-3 overexpression downregulated CYLD mRNA whereas fibulin-3 knockdown caused the opposite effect ( Figure 5b) . Surprisingly, blockade of Notch signaling with the gamma-secretase inhibitor DAPT 17 did not prevent the downregulation of CYLD (Figure 5c ) and the activation of NF-κB p65 (Figure 5d ) by fibulin-3. These results suggested that fibulin-3 may regulate Notch and NF-κB mechanisms independently in GBM. Even if CYLDdownregulation underlies, in part, the activation of NF-κB by fibulin-3, this mechanism does not depend on Notch signaling as postulated in other cancers. This prompted to investigate which other 'nodes' could be regulated by fibulin-3 to result in joint but independent regulation of Notch and NF-κB pathways.
An indirect mechanism by which fibulin-3 can activate Notch in GBM involves increased activity of the metalloproteases ADAM10 and ADAM17, 18 which cleave and activates Notch receptors. 26 These enzymes are also known as TNFα convertases (TACE) because one of their major functions is the cleavage of membrane-bound pro-TNFα to release soluble TNFα, which in turn activates TNF receptors and NF-κB signaling. 27 Therefore, we investigated whether regulation of ADAM10/17 could be a mechanism by which fibulin-3 regulated NF-κB signaling in a parallel and independent manner from Notch signaling.
Overexpression of fibulin-3 in U251 cells significantly increased the expression of ADAM17 mRNA, but not ADAM10 (Figure 6a ), as well as TACE enzymatic activity (Figure 6b ). TACE activity was also increased when purified fibulin-3 was added to lysates of GBM cells (Figure 6b ), suggesting that fibulin-3 directly regulated enzymatic activity of ADAM17 in addition to its expression. Accordingly, fibulin-3 stimulation of GBM cells increased the cleavage of membrane-bound pro-TNFα and the release of soluble TNFα to the culture medium ( Figure 6c ). Moreover, inhibition of TACE activity with the small-molecule inhibitor TAPI-2 was sufficient to abolish the enhancing effect of fibulin-3 on p65 phosphorylation (Figure 6d ), suggesting that this was a key mechanism by which fibulin-3 regulated the NF-κB pathway.
Because ADAM17 seemed to be the TACE enzyme responsive to fibulin-3, we next investigated if these proteins interacted directly to activate NF-κB. We could not detect a significant association between fibulin-3 and ADAM17 by co-immunoprecipitation ( Supplementary Figure 6 ), suggesting that fibulin-3 probably regulated other mediator protein(s) that interact with ADAM17. A well-known inhibitor of ADAM17 is the Tissue Inhibitor of Metalloproteases TIMP3, 28 which also binds to fibulin-3 29 and can be 'sequestered' by fibulin-3 in GBM. 18 Accordingly, the effect of fibulin-3 on NF-κB was inhibited by TIMP3 in a concentrationdependent manner (Figure 6e ), suggesting that fibulin-3 competes with TIMP3 to activate ADAM17. Finally, we used the TNFα small-molecule inhibitor C87, which does not prevent cleavage of pro-TNFα but inhibits the binding of released TNFα to TNF receptors and reduces NF-κB activation. Treatment of fibulin-3overexpressing cells with C87 did not prevent the increase of soluble TNFα but strongly inhibited NF-κB activation (Figure 6f ). Together, these results strongly suggest a model in which fibulin-3 prevents TIMP3 inhibition of ADAM17, resulting in sustained release of TNFα that activates TNF receptors and therefore canonical NF-κB signaling (Figure 6g ). 
DISCUSSION
Dysregulated, constitutive activation of NF-κB signaling is a central mediator of inflammatory and anti-immune processes that correlate with tumor progression. 30, 31 In GBMs, sustained NF-κB activity is necessary for the maintenance of the tumor-initiating cell population 32, 33 and for tumor progression towards a more Fibulin-3 regulates NF-κB signaling in glioma aggressive phenotype 12 that involves enhanced invasion 34 and neo-angiogenesis. 35 NF-κB activation also occurs in tumorassociated astrocytes 36 and microglia, [37] [38] [39] which contribute to tumor progression. Because NF-κB components are rarely mutated in adult GBMs, 40 this suggests that the pathway becomes constitutively activated by alterations in key regulatory mechanisms.
Our results suggest that fibulin-3 is a novel soluble signal that drives NF-κB signaling in GBMs and their microenvironment. Fibulin-3 is one of seven members of the fibulin family that are found in the basal lamina of blood vessels and the ECM of connective tissues. 41 These glycoproteins have been largely regarded as structural components necessary for the mechanical integrity of tissue 42, 43 but their overexpression in cancer has revealed novel roles as soluble signals that facilitate cell adhesion, growth and motility. 44 The upregulation of fibulin-3 in cancer was first described in high-grade gliomas 16 and pancreatic carcinomas, 45 after which this protein was identified as a pro-tumoral factor in several types of metastatic solid tumors. [46] [47] [48] [49] [50] [51] Mechanistically, fibulin-3 has been shown to activate the EGFR/Akt axis in pancreatic cancer cells 52 but this mechanism was not observed in the GBM cells. 17, 53 Instead, we and others demonstrated that fibulin-3 directly activates the Notch pathway in GBM cells 17, 19 and tumorassociated endothelial cells, 18 resulting in increased tumor invasion, angiogenesis and chemoresistance. The current knowledge of fibulin-3 in GBMs underscores this ECM protein not only as a marker of tumor aggressiveness but more importantly as a promoter of malignant progression. 17, 19 Here, we have demonstrated that the effects of fibulin-3 in GBM correlate with, and depend on, activation of canonical NF-κB. Fibulin-3 expression matches NF-κB upregulation in experimental models and clinical data sets, with preferential co-expression in mesenchymal GBMs and in tumor regions populated by invasive cells, all of which makes fibulin-3 a possible marker for regions of active tumor progression. Moreover, our in silico and in vitro data indicate that fibulin-3 promotes invasion in GBM by concerted NF-κB activation both in tumor cells and astroglia (Figures 2 and 4) , driving a NF-κB-dependent proinvasive signature that includes genes for cell adhesion (tenascin-C), motility (MLCK) and ECM remodeling (metalloproteases). Overall, these results suggest that fibulin-3 may be among the key signals that stimulate and sustain NF-κB to favor the malignant progression of GBMs.
The molecular interactions of fibulin-3 with NF-κB regulatory proteins remain to be fully elucidated but our results already indicate that fibulin-3 likely activates NF-κB by preventing TIMP3 inhibition of ADAM17, therefore increasing the activity of this enzyme. This, in turn, increases the availability of soluble TNFα to bind TNF receptors and activate canonical NF-κB. This finding is of particular significance because ADAM17 is a 'master protease' on the cell surface that regulates multiple signaling pathways 54, 55 for tumor growth, invasion, angiogenesis and immune escape. [56] [57] [58] [59] Regulation of ADAM17 activity by fibulin-3 explains the ability of this ECM protein to activate both Notch (by cleavage of Notch-1 receptor) and NF-κB (by shedding of TNFα) in a parallel and independent manner, and suggests that there may be more pathways modulated by fibulin-3 in a similar manner. We acknowledge that some molecular effects of fibulin-3 may not be explained by ADAM17 regulation, such as the dominant inhibition of NF-κB signaling after fibulin-3 knockdown (Figure 1) . It is possible that fibulin-3 downregulation increases CYLD that in turn inhibits NF-κB signaling, but the mechanisms by which fibulin-3 regulates CYLD at the transcriptional level is yet unknown. Further work is needed to identify cell surface mechanisms tonically regulated by fibulin-3 and affected by the loss of this protein.
NF-κB remains a challenging target for molecular therapies because of the multitude of cellular mechanisms controlled by this pathway, which raises concern for the adverse effects that may result from total NF-κB inhibition. 31, 32 New research has focused on inhibiting key NF-κB activating signals, thus disrupting NF-κB transcriptional programs with high-specificity and fewer off-target effects. The oncogenic effect of fibulin-3 on NF-κB is likely a GBMspecific function because fibulin-3 is neither soluble in normal tissues nor expressed in the brain. 16, 60 Therefore, specific targeting of fibulin-3/NF-κB interactions could inhibit tumor progression with potentially limited side effects. We suggest that targeting a fibulin-3/NF-κB axis may provide a novel avenue to improve combination therapies for GBM.
MATERIALS AND METHODS
Cell cultures
GBM cell lines, GBM stem cells, primary mouse astrocytes and human brain microvascular endothelial cells were cultured following standard methods, as described. [16] [17] [18] Human U251 cells were chosen for manipulation with fibulin-3 cDNA or siRNA because they have moderate endogenous levels of fibulin-3 among glioma lines. 16 The rat CNS1 cells were used to study invasion mechanisms because U251 cells are poorly invasive through brain tissue. All cells were authenticated using the 'Cell Check' service (IDEXX-Research Animal Diagnostic Laboratory, Columbia, MO, USA). All supplements were removed from the cultures during in vitro tests requiring addition of fibulin-3 or TNFα.
DNA and RNA constructs
Fibulin-3 cDNA was cloned in the plasmid pcDNA3.1(+) (Life Technologies, Carlsbad, CA, USA) for transient transfections and subcloned into the lentiviral vector pCDH-EF1-copGFP (System Biosciences, Mountain View CA) for constitutive expression in GBM cells. 16 siRNA oligonucleotides against fibulin-3, p65 and CYLD (Qiagen, Valencia, CA, USA) were transfected at 100 pmol/5 × 10 5 cells and validated at the mRNA and protein level 17 (Supplementary Figure 1) . The cells were used in assays or Figure 3 . Fibulin-3 correlates with a NF-κB-regulated invasive signature. (a) Gene expression clustering in GBMs using normalized TCGA data for EFEMP1, EFEMP2, NF-κB transcription factors and fibulin-3-correlated pro-invasive genes tested in Figure 1 . Unsupervised cluster analysis revealed two major patient populations (red and blue lines) characterized by high and low co-expression of these genes. (b) Kaplan-Meier analysis of those two populations showed significantly poorer survival in patients with higher co-expression of fibulin-3 and NF-κB-associated genes (P = 0.014 by log-rank test). (c) Co-expression of fibulin-3 (EFEMP1) and p65 (RELA) was higher in the mesenchymal and classical subtypes of GBMs compared to neural and proneural subtypes. Bars represent the standard error in z-score for each subtype and the size of the circles represent the number of cases for subtype. (d) Intratumoral expression of EFEMP1 and RELA from a set of 10 specimens with 5 histologically defined regions: leading edge (LE); infiltrating tumor (IT); core tumor (CT); pseudopalisading cells around necrosis (PAN); and microvascular proliferation region (MVP). Numbers in parentheses are averaged z-scores for EFEMP1 and RELA expression. Results suggested preferential coexpression of both genes in perinecrotic areas of the tumor. (e) NF-κB-regulated genes that were highly or poorly correlated with fibulin-3 ( Supplementary Table III ) were aggregated into functional networks ( Supplementary Table IV ). Networks were scored (red/green bars) based on the number of NF-κB-regulated genes found in each network (# of focus molecules). NF-κB-regulated genes highly correlated with fibulin-3 were predominantly associated with cellular movement and cell-cell interactions, while genes not correlated with fibulin-3 were involved in cell growth and proliferation and immune responses. (e) CNS1 tumorspheres were also seeded on brain slices from NF-κB-deficient mice (NFκB-def; TNFR1 − / − RelA/p65 − / − ) or their wild-type littermates. NF-κB deficiency in brain tissue abolished cell invasion and the pro-invasive effect of fibulin-3. Results in c-e were analyzed by two-way ANOVA for repeated measures; asterisks indicate differences between fibulin-3-expressing cells and their respective control (*Po0.05; **P o0.01; ***P o0.001).
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Biochemical assays
The transfected cells were lysed and processed for semiquantitative RT-PCR or western blotting using standard protocols 16 (antibodies and primers are listed in Supplementary Tables I and II ). The cultures were treated overnight with the gamma-secretase inhibitor DAPT (25 μM, Tocris Bioscience, Bristol, UK) or the TACE inhibitor TAPI-2 (1 μM, Cayman Chemical, Ann Arbor, MI, USA). The cells were also treated with TNFα (10 ng/ml, Peprotech, Rocky Hill, NJ, USA), fibulin-3 (300 ng/ml, Origene, Rockville, MD, USA) or the TNFα inhibitor C87 (10 μM, Tocris) for 1 to 24 h before collection. For reporter assays, a plasmid carrying Renilla luciferase was co-transfected as loading control.
To measure TACE activity, the cells were lysed in 50 mM Tricine buffer (pH 7.5) containing 100 mM NaCl, 10 mM CaCl 2 , 1 mM ZnCl 2 and 0.1% Triton X-100. Clarified lysates (50 μg total protein) were incubated with a fluorogenic ADAM10/17 substrate peptide (TACE substrate III) as described. 18 
Cell-based assays
To quantify nuclear translocation of p65, the cells were treated with fibulin-3 or TNFα and processed for immunocytochemistry using an antibody against total p65. Nuclear translocation was quantified by co-localization of p65 with nuclear DAPI staining. For cell adhesion assays, the U251 cells were dissociated and seeded (25 000 cells/well) on fibronectin-coated wells (5 μg/ml) for 1 h. The adhered cells were fixed, stained with crystal violet and quantified as described. 16 For cell invasion assays, the CNS1 cells were transfected with combinations of cDNAs and siRNAs and allowed to form tumorspheres for 48 before seeding on brain slices; cell dispersion was quantified by imaging methods as described. 16 The NF-κB inhibitors caffeic acid methyl ester (CAPE, 20 μM, Tocris) or BAY-11-7082 (0.5-5 μM Calbiochem, Billerica, MA, USA) were added to the slice culture medium for the duration of the experiments. To assess the role of microenvironmental NF-κB, spheroids were seeded on brain slices from neonatal NF-κBdeficient mice (TNFR1 − / − p65 − / − , selected from a heterozygous colony) 23 provided by Dr Denis Guttridge (The Ohio State University). To quantify GBM stem cell viability, dissociated cells were transfected with control or fibulin-3 siRNAs and plated in 96-well plates at a density of 2000 cells/well. The cultures were spiked with TNFα (10 ng/ml) every other day after plating. The cell viability was assessed by ATP production using the CellTiter-Glo kit (Promega). 17 
Animal procedures
All the animal experiments were approved by the Animal Care and Use Committees at the Brigham and Women's Hospital and SUNY Upstate Medical University. GFP-expressing CNS1 cells (5 × 10 4 cells in 2 μl) were implanted in the striatum of athymic mice as described. 16, 17 The brains were collected 20 days after tumor implantation and processed for cryosectioning at 20 μm. The sections were fixed in 4% paraformaldehyde and processed for immunohistochemistry to detect p65 and GFAP. The tumor boundaries were identified by GFP expression and high cellular density Figure 6 . Fibulin-3 stimulates ADAM17 to produce TNFα and activate NF-κB. (a) Fibulin-3 overexpression (OE) increased ADAM17 mRNA (***P o0.001, Student's t-test) but not ADAM10 mRNA in U251 cells. (b) Lysates from fibulin-3-overexpressing cells or co-incubated with purified fibulin-3 for 6 h also showed increased ADAM17/TACE enzymatic activity (***Po0.001, one-way analysis of variance (ANOVA)). (c) Fibulin-3 overexpression increased the cleavage of membrane-bound pro-TNFα and release of soluble TNFα, which can activate NF-κB. (d) The enhancing effect of fibulin-3 on p65 phosphorylation (in U251 cells) was blocked by the ADAM17 inhibitor TAPI-2 (1 μM). (e) Activation of NF-κB by fibulin-3 was also inhibited in a concentration-dependent manner by the ADAM17 endogenous inhibitor, TIMP3. The bar graph shows quantitative results from triplicate experiments (significant differences from control cells at ***Po 0.001; one-way ANOVA). (f) The small-molecule inhibitor C87 did not prevent activation of ADAM17 and release of soluble TNFα by fibulin-3, but blocked TNFα and downstream activation of NF-κB. (g) Proposed mechanism of action of fibulin-3 to activate NF-κB via sustained activation of ADAM17 and accumulation of soluble TNFα.
Fibulin-3 regulates NF-κB signaling in glioma calculated using the R's package NBClust. Molecular subtypes of GBM were identified in the TCGA data set using profiles provided by the GBM Bio-Discovery Portal (http://gbm-biodp.nci.nih.gov). 63 RNAseq data (z-scores) for intratumoral expression of EFEMP1 and RELA in histologically defined, microdissected regions from 10 GBM specimens (total N = 122 samples) was obtained from the IVY Glioblastoma Atlas Project repository (http:// glioblastoma.alleninstitute.org)
To perform correlation analysis between fibulin-3 and NF-κB-regulated genes, we first reviewed publically available surveys of predicted and tested NF-κB targets (http://bioinfo.lifl.fr/NF-KB/ and http://www.bu.edu/nfkb/gene-resources/target-genes) 64, 65 to compile a list of 348 genes directly regulated by NF-κB. We next used TCGA GBM microarray data to correlate EFEMP1 with each NF-κB-regulated gene, followed by Bonferroni correction of P-values for multiple comparisons. Correlations were filtered for significance (adjusted Po0.05) and sorted by Pearson's Rho value to select 100 genes with the highest correlation with fibulin-3 (highest absolute Rho values) and 100 genes with the lowest correlation (Rho closest to zero) ( Supplementary Table III ). Each group of genes was separately analyzed using Ingenuity Pathway Analysis (Qiagen) to identify the most represented networks of signaling pathways and cellular functions. Those networks were scored based on how many genes from the original 100-gene list ('focus molecules') were found in each network ( Supplementary Table IV ). This yielded two lists of ranked cellular functions containing NF-κB-regulated genes; one list for genes with highest correlation with fibulin-3 and another for genes with lowest correlation with fibulin-3.
Statistics
Experiments in vitro were repeated in triplicate with three to five independent replicates (eight replicates for invasion assays). The animals studies were performed in duplicate with N = 5 per experimental condition (to detect differences at least twice as large as the s.d. of the groups, at power 80% and Po0.05). Blinding and randomization for animal studies followed the ARRIVE guidelines for animal research. 66 Grubb's test was used to detect outlier results; all differences were deemed significant at Po0.05.
